Clinical and genetic aspects of monogenic obesity

Czech version

Authors: D. Lesayová ^1,2; J. Staník ^1,2; D. Gašperíková ^1,3; I. Klimeš ^1,3
Authors‘ workplace: DIABGENE a Laboratórium diabetu a porúch metabolizmu ÚEE SAV Bratislava, Slovenská republika, vedúci prof. MU Dr. Iwar Klimeš, DrSc. ¹; I. detská klinika Lekárskej fakulty UK a Dérerovej FNsP Bratislava, Slovenská republika, prednostka doc. MU Dr. Oľga Červeňová, CSc. ²; Molekulárno- medicínske centrum SAV Bratislava, Slovenská republika, riaditeľ MU Dr. Richard Imrich, PhD. ³
Published in: Vnitř Lék 2010; 56(10): 1043-1049
Category: Obesity 2010

Overview

High prevalence of obesity in all of age categories is currently one of the biggest problem in medicine. Identification of etiology of obesity can individualise an approach to the patient and it is essential for choosing a target management and therapy. Beside the largest group with polygenic inheritance are clinically important also patients with “syndromic obesity”, where obesity is only one of the signs and monogenic obesity, where obesity is the major clinical phenotype (patients with mutations in gene for leptin, leptine receptor, prohormone convertase 1, melanocortine receptor 4, brain‑derived neurotropic factor and tyrosin kinase receptor B). The monogenic obesity includes 3– 4% of all patients with obesity. This review article brings newest insight on genetics, clinical manifestation, diagnostics and therapy of these diseases.

Key words:
prevalence of obesity – polygenic hereditability of obesity – monogenic obesity

Sources

1. Farooqi S. Obesity genes‑ it’s all about the parents! Cell Metab 2009; 9: 487– 488.

2. Farooqi S, O’Rahilly S. Genetics of obesity in humans. Endocr Rev 2006; 27: 710– 718.

3. Farooqi S, O’Rahilly S. New advances in the genetics of early onset obesity. Int J Obes (Lond) 2005; 29: 1149– 1152.

4. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 1997; 27: 325– 351.

5. Meyre D, Lecoeur C, Delplanque J et al. A genome‑ wide scan for childhood obesity‑associated traits in French families shows significant linkage on chromosome 6q22.31– q23.2. Diabetes 2004; 53: 803– 811.

6. Stunkard AJ, Sørensen TI, Hanis C et al. An adoption study of human obesity. N Engl J Med 1986; 314: 193– 198.

7. Willer CJ, Speliotes EK, Loos RJ et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41: 25– 34.

8. Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: recent advances. Eur Child Adolesc Psychiatry 2010; 19: 297– 310.

9. Hetherington MM, Cecil JE. Gene‑ environment interactions in obesity. Forum Nutr 2010; 63: 195– 203.

10. O’Rahilly S, Farooqi S. Genetics of obesity. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1095– 1105.

11. Santos VM, Henrique de Paula F, Osterne EM et al. Morbid obesity in an adolescent with Prader‑ Willi syndrome. Rev Med Chil 2009; 137: 264– 268.

12. Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic disorders. Endocrinol Metab Clin North Am 2008; 37: 733– 751.

13. Tolson KP, Gemelli T, Gautron L et al. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosci 2010; 30: 3803– 3812.

14. Perrone L, Marzuillo P, Grandone A et al. Chromosome 16p11.2 deletions: another piece in the genetic puzzle of childhood obesity. Ital J Pediatr 2010; 36: 43.

15. de Smith AJ, Purmann C, Walters RG et al. A deletion of the HBII‑ 85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 2009; 18: 3257– 3265.

16. Farooqi S, O’Rahilly S. Mutations in ligands and receptors of the leptin‑melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab 2008; 4: 569– 577.

17. Farooqi S, O’Rahilly S. Monogenic obesity in humans. Annu Rev Med 2005; 56: 443– 458.

18. Hochberg I, Hochberg Z. Hypothalamic obesity. Endocr Dev 2010; 17: 185– 196.

19. Bochukova EG, Huang N, Keogh J et al. Large, rare chromosomal deletions associated with severe early‑ onset obesity. Nature 2010; 463: 666– 670.

20. Lee YS. The role of leptin‑melanocortin system and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore 2009; 38: 34– 41.

21. Coll AP, Farooqi S, O’Rahilly S. The hormonal control of food intake. Cell 2007; 129: 251– 262.

22. Farooqi S. Monogenic human obesity. Front Horm Res 2008; 36: 1– 11.

23. Ichihara S, Yamada Y. Genetic factors for human obesity. Cell Mol Life Sci 2008; 65: 1086– 1098.

24. Krude H, Grüters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab 2000; 11: 15– 22.

25. Kimber W, Peelman F, Prieur X et al. Functional characterization of naturally occurring pathogenic mutations in the human leptin receptor. Endocrinology 2008; 149: 6043– 6052.

26. Tan K, Pogozheva ID, Yeo GS et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 2009; 150: 114– 125.

27. Creemers JW, Lee YS, Oliver RL et al. Mutations in the amino‑terminal region of proopiomelanocortin (POMC) in patients with early‑ onset obesity impair POMC sorting to the regulated secretory pathway. J Clin Endocrinol Metab 2008; 93: 4494– 4499.

28. Tan K, Pogozheva ID, Yeo GS et al. Functional characterization and structural modeling of obesity‑associated mutations in the Melanocortin 4 Receptor. Endocrinology 2009; 150: 114– 125.

29. Kimber W, Peelman F, Prieur X et al. Functional characterisation of naturally occurring pathogenic mutations in the human leptin receptor. Endocrinology 2008; 149: 6043– 6052.

30. Farooqi IS, Bullmore E, Keogh J et al. Leptin regulates striatal regions and human eating behavior. Science 2007; 317: 1355.

31. Farooqi S, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009; 89: 980S– 984S.

32. Farooqi S, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879– 884.

33. Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356: 237– 247.

34. Farooqi S. Insights from the genetics of severe childhood obesity. Horm Res 2007; 68 (Suppl 5): 5– 7.

35. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093– 1103.

36. Oswal A, Yeo GS. The leptin melanocortin pathway and the control of body weight: lessons from human and murine genetics. Obes Rev 2007; 8: 293– 306.

37. Farooqi IS. Monogenic human obesity syndromes. Prog Brain Res 2006; 153: 119– 125.

38. Prieur X, Tung YC, Griffin JL et al. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology 2008; 149: 5432– 5439.

39. Guerra B, Santana A, Fuentes T et al. Leptin receptors in human skeletal muscle. J Appl Physiol 2007; 102: 1786– 1792.

40. Chan LF, Webb TR, Chung TT et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl Acad Sci USA 2009; 106: 6146– 6151.

41. Bicknell AB. The tissue‑ specific processing of pro‑opiomelanocortin. J Neuroendocrinol 2008; 20: 692– 699.

42. Coll AP, Farooqi IS, Challis BG et al. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004; 89: 2557– 2562.

43. Krude H, Biebermann H, Luck W et al. Severe early‑ onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155– 157.

44. Nillni EA. Regulation of prohormone convertases in hypothalamic neurons: implications for prothyrotropin‑releasing hormone and proopiomelanocortin. Endocrinology 2007; 148: 4191– 4200.

45. Bataille D. Pro‑protein convertases in intermediary metabolism: islet hormones, brain/ gut hormones and integrated physiology. J Mol Med 2007; 85: 673– 684.

46. Jackson RS, Creemers JW, Farooqi IS et al. Small‑intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003; 112: 1550– 1560.

47. O’Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. Int J Obes (Lond) 2008; 32 (Suppl 7): S55– S61.

48. Farooqi IS, Volders K, Stanhope R et al. Hyperphagia and early‑ onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/ 3. J Clin Endocrinol Metab 2007; 92: 3369– 3373.

49. Sundaramurthy D, Campbell DA, Leek JP et al. Assignment of the melanocortin 4 receptor (MC4R) gene to human chromosome band 18q22 by in situ hybridisation and radiation hybrid mapping. Cytogenet Cell Genet 1998; 82: 97– 98.

50. Alfieri A, Pasanisi F, Salzano S et al. Functional analysis of melanocortin‑4- receptor mutants identified in severely obese subjects living in Southern Italy. Gene 2010; 457: 35– 41.

51. Chai B, Li JY, Zhang W et al. Melanocortin‑4 receptor activation inhibits c‑ Jun N‑terminal kinase activity and promotes insulin signaling. Peptides 2009; 30: 1098– 1104.

52. Masuzaki H, Tanaka T, Ebihara K et al. Hypothalamic melanocortin signaling and leptin resistance – perspective of therapeutic application for obesity‑ diabetes syndrome. Peptides 2009; 30: 1383– 1386.

53. Tao YX. The melanocortin‑4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010; 31: 506– 543.

54. Farooqi IS, Keogh JM, Yeo GS et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348: 1085– 1095.

55. Lee YS, Poh LK, Kek BL et al. Novel melanocortin 4 receptor gene mutations in severely obese children. Clin Endocrinol (Oxf) 2008; 68: 529– 535.

56. Petry CJ, López‑ Bermejo A, Díaz M et al. Association between a common variant near MC4R and change in body mass index develops by two weeks of age. Horm Res Paediatr 2010; 73: 275– 280.

57. Rettenbacher E, Tarnow P, Brumm H et al. A novel non‑synonymous mutation in the melanocortin‑4 receptor gene (MC4R) in a 2‑year‑ old Austrian girl with extreme obesity. Exp Clin Endocrinol Diabetes 2007; 115: 7– 12.

58. Wangensteen T, Kolsgaard ML, Mattingsdal M et al. Mutations in the melanocortin 4 receptor (MC4R) gene in obese patients in Norway. Exp Clin Endocrinol Diabetes 2009; 117: 266– 273.

59. Stutzmann F, Tan K, Vatin V et al. Prevalence of melanocortin‑4 receptor deficiency in Europeans and their age‑ dependent penetrance in multigenerational pedigrees. Diabetes 2008; 57: 2511– 2518.

60. Maier T, Hoyer J. Modulation of blood pressure by central melanocortinergic pathways. Nephrol Dial Transplant 2010; 25: 674– 677.

61. Sayk F, Heutling D, Dodt C et al. Sympathetic function in human carriers of melanocortin‑4 receptor gene mutations. J Clin Endocrinol Metab 2010; 95: 1998– 2002.

62. Hainerova I, Larsen LH, Holst B et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab 2007; 92: 3689– 3696.

63. Szewczyk JR, Laudeman CP, SammondDM et al. A concise synthesis of 1,4- dihy-dro‑[1,4]diazepine‑ 5,7- dione, a novel 7-TMreceptor ligand core structure with melano-cortin receptor agonist activity. Bioorg Med Chem 2010; 18: 1822– 1833.

64. Reinehr T, Hebebrand J, Friedel S et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity (Silver Spring) 2009; 17: 382– 389.

65. Loos RJ, Rankinen T, Tremblay A et al. Melanocortin‑4 receptor gene and physical activity in the Quebec Family Study. Int J Obes (Lond) 2005; 29: 420– 428.

66. Price RD, Milne SA, Sharkey J et al. Advances in small molecules promoting neurotrophic function. Pharmacol Ther 2007; 115: 292– 306.

67. Dhillo WS. Appetite regulation: an overview. Thyroid 2007; 17: 433– 445.

68. Gray J, Yeo GS, Cox JJ et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain‑derived neurotrophic factor (BDNF) gene. Diabetes 2006; 55: 3366– 3371.